vs
CITIUS ONCOLOGY, INC.（CTOR）与INTELLIGENT PROTECTION MANAGEMENT CORP.（IPM）财务数据对比。点击上方公司名可切换其他公司
INTELLIGENT PROTECTION MANAGEMENT CORP.的季度营收约是CITIUS ONCOLOGY, INC.的1.6倍（$6.1M vs $3.9M）
Citius Oncology是一家处于后期阶段的生物制药企业，专注于开发针对癌症患者的创新靶向疗法，核心管线覆盖血液恶性肿瘤和实体瘤领域的未满足医疗需求，主要服务北美及全球肿瘤诊疗市场。
智能防护管理公司是一家总部位于英国格洛斯特郡的控股母公司，于2008年5月21日完成注册。公司为旗下四家子公司提供集团管理架构，其前身是专精于情报搜集、反间谍与反窃听检测业务的国际情报有限公司。
CTOR vs IPM — 直观对比
营收规模更大
IPM
是对方的1.6倍
$3.9M
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.9M | $6.1M |
| 净利润 | $-5.5M | — |
| 毛利率 | 80.0% | 53.1% |
| 营业利润率 | -133.2% | -13.4% |
| 净利率 | -140.3% | — |
| 营收同比 | — | 2091.6% |
| 净利润同比 | 16.9% | — |
| 每股收益（稀释后） | $-0.06 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTORIPM
| Q4 25 | $3.9M | $6.1M | ||
| Q3 25 | — | $6.2M | ||
| Q2 25 | — | $5.7M | ||
| Q1 25 | — | $5.5M | ||
| Q4 23 | — | $-7.3M | ||
| Q3 23 | — | $2.8M | ||
| Q2 23 | — | $3.0M | ||
| Q1 23 | — | $2.6M |
净利润CTORIPM
| Q4 25 | $-5.5M | — | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | — | $-1.1M | ||
| Q1 25 | — | $808.5K | ||
| Q4 23 | — | — | ||
| Q3 23 | — | $-181.6K | ||
| Q2 23 | — | $135.6K | ||
| Q1 23 | — | $-738.3K |
毛利率CTORIPM
| Q4 25 | 80.0% | 53.1% | ||
| Q3 25 | — | 50.7% | ||
| Q2 25 | — | 50.1% | ||
| Q1 25 | — | 55.3% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | 70.1% | ||
| Q2 23 | — | 73.8% | ||
| Q1 23 | — | 68.7% |
营业利润率CTORIPM
| Q4 25 | -133.2% | -13.4% | ||
| Q3 25 | — | -23.0% | ||
| Q2 25 | — | -19.7% | ||
| Q1 25 | — | -24.2% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | -14.1% | ||
| Q2 23 | — | -9.4% | ||
| Q1 23 | — | -35.5% |
净利率CTORIPM
| Q4 25 | -140.3% | — | ||
| Q3 25 | — | -17.4% | ||
| Q2 25 | — | -18.3% | ||
| Q1 25 | — | 14.7% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | -6.6% | ||
| Q2 23 | — | 4.6% | ||
| Q1 23 | — | -28.8% |
每股收益（稀释后）CTORIPM
| Q4 25 | $-0.06 | $-0.05 | ||
| Q3 25 | — | $-0.08 | ||
| Q2 25 | — | $-0.08 | ||
| Q1 25 | — | $0.06 | ||
| Q4 23 | — | $-0.03 | ||
| Q3 23 | — | $-0.02 | ||
| Q2 23 | — | $0.01 | ||
| Q1 23 | — | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.3M | $5.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $58.4M | $18.2M |
| 总资产 | $110.0M | $26.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTORIPM
| Q4 25 | $7.3M | $5.6M | ||
| Q3 25 | — | $7.3M | ||
| Q2 25 | — | $7.3M | ||
| Q1 25 | — | $9.7M | ||
| Q4 23 | — | $13.6M | ||
| Q3 23 | — | $13.7M | ||
| Q2 23 | — | $13.7M | ||
| Q1 23 | — | $13.9M |
股东权益CTORIPM
| Q4 25 | $58.4M | $18.2M | ||
| Q3 25 | — | $18.8M | ||
| Q2 25 | — | $19.9M | ||
| Q1 25 | — | $21.1M | ||
| Q4 23 | — | $20.1M | ||
| Q3 23 | — | $20.4M | ||
| Q2 23 | — | $20.5M | ||
| Q1 23 | — | $20.3M |
总资产CTORIPM
| Q4 25 | $110.0M | $26.0M | ||
| Q3 25 | — | $27.2M | ||
| Q2 25 | — | $29.8M | ||
| Q1 25 | — | $31.1M | ||
| Q4 23 | — | $23.9M | ||
| Q3 23 | — | $24.1M | ||
| Q2 23 | — | $24.4M | ||
| Q1 23 | — | $24.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-7.4M | $87.6K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CTORIPM
| Q4 25 | $-7.4M | $87.6K | ||
| Q3 25 | — | $133.0K | ||
| Q2 25 | — | $-888.7K | ||
| Q1 25 | — | $1.7M | ||
| Q4 23 | — | $-99.0K | ||
| Q3 23 | — | $16.1K | ||
| Q2 23 | — | $-193.8K | ||
| Q1 23 | — | $-803.0K |
资本支出强度CTORIPM
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
现金转化率CTORIPM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 2.16× | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | -1.43× | ||
| Q1 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTOR
暂无分部数据
IPM
| Procurement Revenue | $5.4M | 88% |
| Other | $743.9K | 12% |
